Bristol-Myers Squibb Company (BMY)
BMY moved a median of -0.02% 30 minutes after news, and -0.00% by the close. How BMY actually reacts to news — the realized, point-in-time move the market made, measured across 642 labeled events over the last three years with zero look-ahead.
BMY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.05% | 44% | 640 |
| 30-min | -0.02% | 45% | 640 |
| 60-min | +0.06% | 51% | 640 |
| to close | -0.00% | 49% | 638 |
| Middle 50% of BMY reactions | -0.42% to +0.46% |
|---|---|
| Median reaction (30-min) | -0.02% |
| Measured reactions | 642 |
Half of all Bristol-Myers Squibb Company news events land between -0.42% and +0.46% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BMY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 40 | -0.36% | 33% | -0.57% |
| Analyst downgrades | 39 | -0.36% | 31% | -0.51% |
| Coverage initiations | 28 | +0.02% | 57% | +0.02% |
| Rating reiterations | 110 | -0.04% | 47% | +0.06% |
| Price-target raises | 22 | -0.12% | 41% | -0.44% |
| Price-target cuts | 17 | +0.10% | 65% | -0.27% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how BMY ranks against every other measured name →
That’s how BMY usually reacts — get an email when it moves on news →Email me when BMY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BMY's baseline. Nothing else.
Recent BMY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint | Press release | Business Wire | +1.27% | -3.49% | |
| Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs | Press release | Business Wire | +1.27% | -3.49% | |
| Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3... | Press release | Business Wire | +0.39% | +0.81% | |
| Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement | Press release | Business Wire | +0.32% | -1.19% | |
| U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* | Press release | Business Wire | +0.32% | -1.19% | |
| Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma | Press release | Business Wire | +0.14% | +1.68% | |
| Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026 | Press release | Business Wire | +0.13% | +0.56% | |
| Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years | Press release | Business Wire | -0.09% | -2.10% | |
| The Melanoma Research Foundation Launches its Annual Los Angeles 5K Fundraiser with a Goal of $100,000 in Support of Melanoma Research, Education and Advocacy | Press release | PR Web | +0.02% | -0.90% | |
| Bristol Myers Squibb Announces Dividend | Press release | Business Wire | +0.30% | -0.73% | |
| Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... | Press release | Business Wire | -1.36% | -1.15% | |
| Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 | Press release | Business Wire | -0.35% | +0.84% | |
| A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity | Press release | GlobeNewswire | +0.31% | -0.04% | |
| Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma | Press release | PR Web | +0.91% | +1.70% | |
| U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse | Press release | Business Wire | -0.73% | -0.27% | |
| Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas | Press release | Business Wire | +0.45% | — | |
| Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 | Press release | Business Wire | +0.56% | +3.46% | |
| Form 10-Q BRISTOL MYERS SQUIBB CO For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.13% | +2.08% | |
| Form 8-K BRISTOL MYERS SQUIBB CO For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | +3.46% | |
| Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA | Press release | Business Wire | +0.12% | -0.99% | |
| U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma | Press release | Business Wire | -0.12% | +2.49% | |
| Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 | Press release | Business Wire | -0.72% | -2.10% | |
| BREYANZI® CAR T Cell Therapy Monitoring and Activity Updates Approved in Canada | Press release | Canada Newswire | +0.20% | -0.93% | |
| Bristol Myers Squibb Announces Dividend | Press release | Business Wire | -0.72% | -2.10% | |
| Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease | Press release | Business Wire | +0.10% | -2.78% | |
| Form 11-K BRISTOL MYERS SQUIBB CO For: Dec 31 | SEC filing · Form 11-K | SEC EDGAR | +0.07% | -0.05% | |
| Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma | Press release | Business Wire | +1.33% | -0.58% | |
| Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma | Press release | Business Wire | -1.87% | -3.77% | |
| U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) | Press release | Business Wire | -1.87% | -3.77% | |
| Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma | Press release | Business Wire | +0.04% | +0.32% | |
| Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | -1.16% | -0.88% | |
| The Melanoma Research Foundation Launches its Annual Denver 5K Fundraiser with a Goal of $100,000 in Support of Melanoma Research, Education and Advocacy | Press release | PR Web | -0.47% | -2.67% | |
| Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline | Press release | Business Wire | +0.03% | -0.98% | |
| Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations | Press release | Business Wire | -0.24% | -0.22% | |
| Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults | Press release | Business Wire | -0.32% | -0.30% | |
| Form 8-K BRISTOL MYERS SQUIBB CO For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | -1.10% | |
| Form S-8 BRISTOL MYERS SQUIBB CO | SEC filing · Form S-8 | SEC EDGAR | +0.04% | -1.10% | |
| Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026 | Press release | Business Wire | -0.08% | -1.12% | |
| Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™ | Press release | Business Wire | +0.16% | -0.47% | |
| Bristol Myers Squibb Reports First Quarter Financial Results for 2026 | Press release | Business Wire | -0.03% | +5.03% | |
| Form 10-Q BRISTOL MYERS SQUIBB CO For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.06% | +0.38% | |
| Form 8-K BRISTOL MYERS SQUIBB CO For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | +5.03% | |
| Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company | Press release | Business Wire | +0.39% | -0.26% | |
| Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion | Press release | Business Wire | -2.00% | +0.41% | |
| Form DEFA14A BRISTOL MYERS SQUIBB CO | SEC filing · Form DEFA14A | SEC EDGAR | -0.67% | -1.45% | |
| Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years | Press release | Business Wire | -0.08% | +0.75% | |
| Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) | Press release | Business Wire | -0.72% | +0.13% | |
| Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride) | Press release | Business Wire | -0.72% | +0.13% | |
| Form 15-12G BRISTOL MYERS SQUIBB CO | SEC filing · Form 15-12G | SEC EDGAR | -0.72% | +0.13% | |
| Form ARS BRISTOL MYERS SQUIBB CO For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.28% | +1.12% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BMY section they belong to.
Where else BMY is measured.
BMY earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Sierra Oncology, Inc. (SRRA) | 649 | -0.03% | 43% |
| Catabasis Pharmaceuticals, Inc. (CATB) | 647 | -0.14% | 45% |
| Five Star Senior Living Inc. - Common Shares (FVE) | 642 | 0.00% | 44% |
| Apollo Endosurgery, Inc. (APEN) | 640 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Bristol-Myers Squibb Company's median reaction calculated?
Every labeled BMY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 642 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of BMY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BMY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.